Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q2 2022 Results - Earnings Call Transcript
02:15pm, Wednesday, 03'rd Aug 2022
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2022 Earnings Conference Call August 3, 2022 9:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
12:02pm, Wednesday, 03'rd Aug 2022
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates
09:47am, Wednesday, 03'rd Aug 2022
Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) to Report Q2 Earnings: What's in Store?
01:56pm, Monday, 25'th Jul 2022
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
08:30am, Monday, 11'th Jul 2022
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
Here's Why Investors Should Retain Charles River (CRL) Now
01:59pm, Tuesday, 05'th Jul 2022
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
02:38pm, Tuesday, 28'th Jun 2022
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Charles River Laboratories: High-Quality Company At A Fair Price
12:02am, Wednesday, 22'nd Jun 2022
CRL is a high-quality business that operates quietly and unnoticed in the background. It has consistently grown revenue, earnings and free cash flow over the years.
Charles River (CRL) Prospers Internationally Amid FX Headwind
11:56am, Tuesday, 21'st Jun 2022
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
12:24pm, Tuesday, 14'th Jun 2022
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Charles River Labs stock slides 6% premarket after company issues profit warning for Q2
07:33am, Wednesday, 08'th Jun 2022
Charles River Laboratories International Inc. shares CRL, +0.89% slid 6% in premarket trade Wednesday, after the drug company issued a profit warning for the second quarter. The company is now expecte
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
11:18am, Friday, 03'rd Jun 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Charles River (CRL) Stock for Now
01:32pm, Monday, 16'th May 2022
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q1 2022 Earnings Call Transcript
02:23pm, Wednesday, 04'th May 2022
Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2022 Earnings Conference Call May 4, 2022 9:30 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman, President and CEO
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
12:47pm, Wednesday, 04'th May 2022
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
